Biomerica (NASDAQ:BMRA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Share on StockTwits

Biomerica (NASDAQ:BMRA) issued its earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03), Fidelity Earnings reports. Biomerica had a negative return on equity of 40.08% and a negative net margin of 52.42%.

NASDAQ:BMRA traded down $0.36 during trading on Friday, reaching $5.70. The company’s stock had a trading volume of 419,885 shares, compared to its average volume of 1,561,208. The firm has a market cap of $66.99 million, a price-to-earnings ratio of -17.66 and a beta of -0.47. Biomerica has a 12 month low of $2.05 and a 12 month high of $23.39. The firm has a 50 day moving average of $5.75 and a 200-day moving average of $7.05.

In related news, Director Catherine Coste purchased 9,100 shares of Biomerica stock in a transaction that occurred on Monday, October 26th. The stock was bought at an average price of $5.45 per share, for a total transaction of $49,595.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 23.70% of the company’s stock.

A number of research analysts have weighed in on the stock. Colliers Securities assumed coverage on shares of Biomerica in a research note on Tuesday, November 10th. They issued a “buy” rating and a $13.00 price objective on the stock. B. Riley cut their price target on Biomerica from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Aegis lowered their price objective on Biomerica from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, October 19th.

About Biomerica

Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.

Recommended Story: How to Invest in a Bull Market

Earnings History for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.